While Car3 could be a biomarker for fatty liver disease in DIO mice, it is also possible that the effect of decreased Car3 seen in niclosamide-treated mouse livers may simply reflect lower fat content in the tissue, without regulating its decrease. Here, CA3 is linked to fatty liver disease.